Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors

Comprehensive genomic profiling (CGP) is crucial in precision oncology, yet its real-world utility remains unclear. Here we analyzed data from the Japanese nationwide Center for Cancer Genomics and Advanced Therapeutics database, including clinical and genetic data from 54,185 patients with advanced solid tumors (consisting of 81 common and rare tumor types) who received CGP with a targeted sequencing panel covering 324 genes as part of their clinical care. We assessed the prognostic value of CGP-guided clinical evidence-level classification, showing that alterations predicting response to Pharmaceuticals and Medical Devices Agency-approved or Food and Drug Administration-approved therapies and to therapies…

• TS
  Takeda Science Foundation
• UM
  Uehara Memorial Foundation
• JA
  Japan Agency for Medical Research and Development

  Award: JP22ama221510, JP25ama221543, and JP25gm1810002h0004
• KF
  Kobayashi Foundation for Cancer Research
• JS
  Japan Society for the Promotion of Science

  Award: JP 22K20808 and JP25K18889
• JS
  Japan Science and Technology Agency

  Award: JPMJMS2022
• MR
  Moonshot Research and Development Program

  Award: JPMJMS2022